Retinal Health Research
Our research is targeting key mechanisms in the pathogenesis of retinal diseases – vascular dysfunction, neuronal dysfunction and neuronal inflammation.
Search
“My ultimate goal is to cure cancer”
Norbert Kraut, our Global Head of Cancer Research, shares how we are advancing science to bring new treatment options for people living with cancer.
expanded-collaboration-MD-Anderson
The continued collaboration aims to accelerate the development of KRAS and TRAILR2 compounds in lung cancer
Strategic-collaboration-with-EnaraBio
Boehringer Ingelheim and Enara Bio enter strategic collaboration and licensing agreement to discover novel shared antigens for cancer immunotherapies.
clinical-collaboration-with-Amgen
Collaboration to study Boehringer Ingelheim’s SOS1::pan-KRAS Inhibitor in combination with Amgen’s KRASG12C Inhibitor
Partnering pet therapeutics
Learn more about our research focus and our most recent partnerships regarding pet therapeutics.
Agreement-to-acquire-NBE-Therapeutics
Boehringer Ingelheim to acquire NBE-Therapeutics to significantly enhance cancer pipeline portfolio with antibody-drug conjugates.
Win Fight Against Cancer
At Boehringer Ingelheim we are giving patients new hope. We are collaborating with the oncology community on a shared journey to deliver leading science.
collaboration-proxygen-molecular-glue-degraders
Boehringer Ingelheim collaborates with Proxygen to explore molecular glue degraders – a novel approach to fight cancer.
Accelerating new cancer medicines in partnership with CBmed
Boehringer Ingelheim and CBmed join forces to translate novel cancer therapy approaches faster into new medicines for patients
clinical_collaboration_with_Mirati
Boehringer Ingelheim and Mirati are teaming up in a clinical collaboration to evaluate the combination of the SOS1::pan-KRAS and the selective G12C inhibitor.
Option to Acquire Trutino Biosciences
Option to Acquire Trutino Biosciences
Facing lung cancer
Keith and Heather talk about their experiences of facing lung cancer as a family and finding purpose after treatment.
SIRPα Cancer Immunology Research
Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.
Boehringer Ingelheim invests in precision cancer treatments
Boehringer Ingelheim Venture Fund invests in Synthetica as part of its commitment to advancing innovative, next-generation cancer therapies
License deal with A*STAR to develop cancer antibodies
License deal with A*STAR to develop cancer antibodies
Protein Degraders in Cancer
Boehringer Ingelheim scientists and their partners are exploring how protein degraders could bring so-called undruggable cancer targets within reach
Boehringer Ingelheim Innovation Prize
Find out more about how we’re providing valuable resources to life-science innovators to enable new and emerging science
Second cancer immunotherapy partnership with 3T Bio
Second cancer immunotherapy partnership with 3T Bio
Targeting HER2 in cancer: The story of zongertinib
We discovered zongertinib, an HER2 tyrosine kinase inhibitor, being developed as a potential oral treatment for people with HER2-mutated NSCLC
Advancing health: Our impactful R&D investments
Discover how we’re investing in sustainable impact with an unwavering commitment to research and development
Sarcoma
Hear from Gary Schwartz, MD, Director of the Case Comprehensive Cancer Center, Cleveland, Ohio, talk about his expert perspectives on sarcoma.
Our Vision
At Boehringer Ingelheim, we have expanded our global research and development activities to tackle eye diseases, specifically those affecting the back of the eye.
Technologies
We are expanding our global network of technology partners Learn more about partnering with us.
Are combination therapies the answer to battling KRAS cancers?
Dr Ulrich Dünzinger and Kristie Fernamberg talk about their work with the SOS1 KRAS inhibitor to block tumour-triggering signal